Loading
Life sciences · Interventional Study
ClinicalTrials.gov · November 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07926542). This is a study registration, not published results. Lead sponsor: Centro Hospitalar de Lisboa Central. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 40 participants (ACTUAL). Conditions: Conscious Sedation, Lung Neoplasms, Lymphadenopathy (Mediastinal). Interventions: DRUG: Dexmedetomidine; DRUG: Midazolam; DRUG: fentanyl. Primary outcome measures: Patient Discomfort Assessed by Visual Analogue Scale , Baseline/Day 1; Physician-Rated Procedural Difficulty Assessed by Visual Analogue Scale , Baseline/Day 1. Brief summary: Endobronchial ultrasound (EBUS) is commonly performed under moderate sedation with midazolam and fentanyl, but patients may still experience discomfort and procedures can be technically demanding. Dexmedetomidine is a sedative that causes little respiratory depression. This randomized trial evaluated whether adding a continuous dexmedetomidine infusion to standard midazolam-fentanyl sedation reduces patient discomfort and procedural difficulty during EBUS, compared with midazolam-fentanyl alone.